IMD receives €4m equity investment from Zhejiang Hisun Pharmaceutical

Collaboration provides access to unique natural preservative technologies

IMD Natural Solutions (INS), a natural product company, has announced a collaboration with Zhejiang Hisun Pharmaceutical under which INS receives a €4m equity investment and provides Hisun access to INS' unique natural product lead discovery platform for antimicrobials and antioxidants for the food, beverage and personal care industries.

Furthermore, INS will benefit from Hisun's production know-how and capabilities.

The investment paves the way for INS to further develop and commercialise its innovative antimicrobial preservation product for use in food, beverage and personal care applications. It is a new, fermentation-based all-natural agent with superior efficacy against yeasts, moulds and other microbial strains and has shown bioactivity against microbial organisms that have adapted to current preservative agents.

The collaboration provides Hisun access to INS's natural product databases and technology for the identification and development of suitable active natural ingredients for various life science applications.

'The investment by Hisun into INS and our access to Hisun's production know-how and capabilities are an important step in driving our core product towards market entry,' said Dr Thomas Henkel, Managing Director of INS.

'The combination of INS's natural product platform and product candidates with Hisun's production know-how creates a unique platform for the development and commercialisation of new, innovative products and thus strengthens our market position and pipeline potential substantially,' said Mr Bai Hua, President and CEO of Hisun.